Posted by Michael Wonder on 12 Apr 2017
Pharma companies are seeking a new treatment — for the backlash against high drug prices
12 April 2017 - Neurocrine Biosciences’ new drug will probably cost $60,000 a year. But the company is waiting until May to release the price.
The San Diego, Ca.-based biotech Neurocrine Biosciences Inc. just got the first U.S. drug approved for adults with the neurological disorder tardive dyskinesia.
But those with the disorder — involuntary body movements that are a side effect of antipsychotic medications — will have to wait to find out how much the drug will cost. And it’s part of a larger trend among drugmakers to tamp down backlash over high prices that could then hit their stock price.
Neurocrine Biosciences is waiting until sales representatives for the drug are sent out next month, President and Chief Operating Officer David-Alexandre Gros said on Tuesday, so the company can “announce pricing in an environment where we can articulate the value to our stakeholders.”
